AWM
KPTI icon

Avior Wealth Management’s Karyopharm Therapeutics KPTI Stock Holding History

Avior Wealth Management’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1
Closed -$33 – 3034
2024
Q1 		$33 Buy
+1
New +$18 ﹤0.01% 3585

Other funds holding KPTI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Avior Wealth Management's KPTI Position: Q2 2024 in Review

Avior Wealth Management sold out of Karyopharm Therapeutics (KPTI) in Q2 2024, closing a stake of 1 share — an estimated $33 sold.

Avior Wealth Management first reported a position in KPTI in Q1 2024 and held it in 1 quarter. The position peaked at $33 in Q1 2024. 114 funds tracked by Wall St. Rank hold KPTI as of Q2 2024.

  • Avior Wealth Management reported no remaining Karyopharm Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Avior Wealth Management sold 1 Karyopharm Therapeutics share in Q2 2024, an estimated $33.
  • Avior Wealth Management first reported a position in Karyopharm Therapeutics in Q1 2024 and held it in 1 quarter.
  • Avior Wealth Management's Karyopharm Therapeutics position peaked at $33 in Q1 2024.
  • 114 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2024.

Based on Avior Wealth Management's 13F filing for Q2 2024, filed 13 Aug 2024.